4 research outputs found
ΠΡΠΎΠ±Π»ΠΈΠ²ΠΎΡΡΡ ΡΠΌΡΠ½ΠΎ-Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ° ΠΌΡΠΊΡΠΎΠ±ΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΡ Ρ ΠΆΡΠ½ΠΎΠΊ Π· ΡΡΠ·Π½ΠΈΠΌΠΈ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΡΡΠ½ΠΈΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΏΠΎΠ»ΡΠΏΡΠ² Π΅Π½Π΄ΠΎΠΌΠ΅ΡΡΡΡ
ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ 58 ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΠΏΠΎΠ»ΠΈΠΏΠ°ΠΌΠΈ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ. ΠΡΡΠ²Π»Π΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ
ΠΏΠ΅ΠΉΠ·Π°ΠΆΠ°, Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΠΌ ΠΏΠΎΠ»ΠΈΠΏΠΎΠ² ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ.
ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» Π²ΡΠ΄Π΅Π»ΠΈΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΈΡΠΊΠ° ΠΏΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΠΎΠ»ΠΈΠΏΠΎΠ² ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ. ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ
ΠΏΠΎΠ»ΠΈΠΏ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ ΡΠ»Π΅Π΄ΡΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ Π½Π΅ ΠΊΠ°ΠΊ ΠΌΠ΅ΡΡΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡ, Π° ΠΊΠ°ΠΊ ΡΠ΅Π°ΠΊΡΠΈΡ ΡΠ½Π΄ΠΎΠΌΠ΅ΡΡΠΈΡ Π² ΠΎΡΠ²Π΅Ρ Π½Π°
ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ Π³ΠΎΠΌΠ΅ΠΎΡΡΠ°Π·Π°, ΡΡΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΏΡΠΈ Π²ΡΠ±ΠΎΡΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΡ
Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ58 women with endometrial polyps were investigated. Specific microflora and hormonal and immune status
depending on the morphological forms of endometrial polyps were found. The analysis performed allowed to
allocate risk groups according to development of endometrial polyp. It was shown that endometrial polyp shall be
considered as endometrial reaction in response to hormonal and immune homeostasis disorder, rather than local
process. This should be borne in mind when choosing treatment for this patholog
Discrepancies between medication records of anticoagulation clinics and pharmacy records
PURPOSE: To determine whether there were discrepancies between with coumarin anticoagulants interacting medications recorded in medical files of anticoagulation clinics (AC-records) and computerized records of community pharmacies (pharmacy records). METHODS: A descriptive study was conducted at two Dutch anticoagulation clinics (AC's). Records of with coumarin anticoagulants interacting drugs at the AC's were compared with the pharmacy records. A drug registered in the pharmacy records but not in the AC-records, was recorded as a discrepancy, while a drug registered in AC-records as well as in pharmacy records, was recorded as a match. RESULTS: Of the 117 identified interacting drugs registered in pharmacy records 32 (27%) were not registered in the AC-records. In four out of seven patients of whom the use of a pharmacokinetically interacting drug was not registered in the AC-records, several INR-values exceeded the upper therapeutic range. CONCLUSION: This study demonstrates that a substantial percentage of drugs of which an interaction with coumarin anticoagulants can be expected, is not registered in the medical files of anticoagulation clinics
Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon
Treatment with vitamin K antagonists (VKAs) has to be interrupted when invasive procedures are planned. We compared various methods of interruption in patients on acenocoumarol or phenprocoumon in a prospective study. In patients on acenocoumarol (n = 141), 99 stopped three days before the intervention and 42 stopped two days before. All patients on phenprocoumon (n = 111) received vitamin K two days before the intervention, and 55 of these patients discontinued phenprocoumon, whereas 56 did not stop. In a subset of 30 patients we determined International Normalized Ratios (INRs) and coagulation factors II, VII, X and protein C. The mean INR after stopping acenocoumarol for three days was significantly lower than after two days (1.1 vs. 1.3, p = <0.0001), but its clinical relevance may be trivial. In patients using phenprocoumon, the mean INR on the day of the intervention was only slightly lower after stopping the VKAs (1.5 vs. 1.6, p = 0.0407), but a similar proportion of patients had an INR <or=1.4. On the day of the intervention, in the acenocoumarol group mean plasma levels of all coagulation factors were higher than 50% and in the phenprocoumon group higher than 25%. We conclude that acenocoumarol can be stopped two days before an invasive procedure that is associated with a low or moderate bleeding risk and three days before an intervention with a higher bleeding risk. For phenprocoumon, administration of vitamin K two days before an intervention results in an acceptable INR during the intervention, regardless whether phenprocoumon is interrupted or no
Discrepancies between medication records of anticoagulation clinics and pharmacy records
PURPOSE: To determine whether there were discrepancies between with coumarin anticoagulants interacting medications recorded in medical files of anticoagulation clinics (AC-records) and computerized records of community pharmacies (pharmacy records). METHODS: A descriptive study was conducted at two Dutch anticoagulation clinics (AC's). Records of with coumarin anticoagulants interacting drugs at the AC's were compared with the pharmacy records. A drug registered in the pharmacy records but not in the AC-records, was recorded as a discrepancy, while a drug registered in AC-records as well as in pharmacy records, was recorded as a match. RESULTS: Of the 117 identified interacting drugs registered in pharmacy records 32 (27%) were not registered in the AC-records. In four out of seven patients of whom the use of a pharmacokinetically interacting drug was not registered in the AC-records, several INR-values exceeded the upper therapeutic range. CONCLUSION: This study demonstrates that a substantial percentage of drugs of which an interaction with coumarin anticoagulants can be expected, is not registered in the medical files of anticoagulation clinics